https://scholar.dgist.ac.kr/handle/20.500.11750/10138 2026-04-27T19:53:44Z https://scholar.dgist.ac.kr/handle/20.500.11750/60249 Title: 습윤 셀룰로오스 및 폴리올레핀 수지가 균일하게 혼합된 셀룰로오스 복합 소재 및 이의 제조방법 Author(s): 이세근; 이영재; 권미경; 이성준; 황준성 Abstract: 본 발명은 습윤 셀룰로오스 및 폴리올레핀 수지가 균일하게 혼합된 셀룰로오스 복합 소재 및 이의 제조방법에 관한 것이다. 구체적으로 폴리올레핀 수지, 팽윤된 셀룰로오스, 말레산 무수물 및 개시제를 용융 혼련하여 제조된 셀룰로오스 복합소재로서, 상기 팽윤된 셀룰로오스는 셀룰로오스를 알칼리 수용액에 처리 후, 산 처리하여 제조된 것인, 셀룰로오스 복합 소재를 제공함으로써, 균일하게 혼합되며, 기계적 물성이 매우 우수한 셀룰로오스 복합 소재를 제공할 수 있다. https://scholar.dgist.ac.kr/handle/20.500.11750/60155 Title: 코로나바이러스 감염증 COVID-19 치료용 펩타이드 및 이의 용도 Author(s): 이영호; 김민기; 권욱봉; 서소욱; 박송; 민가희; 이주환; 지상호; 장익수; 김상열; 유우경; 김효은; 최재석; 김희연; 박성준; 추효섭; 오명원; 이애리; 강무석; 이경은; 최성균; 최민지 Abstract: The present invention relates to a peptide for treatment of the corona virus infection COVID-19 and a use thereof. In order to make the binding to the new epitope of SARS-CoV2 RBD stronger compared to the peptide (P6) simulating the conventionally known binding site between SARS-CoV RBD and ACE2, the peptide of the present invention includes a new portion added with a novel amino acid sequence fundamentally designed for interaction in the dimension of atoms consisting of the amino acids. Suggested in the present invention is a novel design of a peptide having higher binding affinity than conventionally known peptides, wherein an expanded peptide is creatively designed to additionally interact with charged amino acids of D420 and K458, located at the rear side of the known binding boundary between RBD and hACE2. The peptide of the present invention exhibits high possibility as a therapeutic agent for COVID-19. https://scholar.dgist.ac.kr/handle/20.500.11750/60140 Title: CARS 현미경 및 이의 제어 방법 Author(s): 이관진; 김현민 Abstract: CARS 현미경이 개시된다. 본 CARS 현미경은 복수의 빔을 발생시키는 광원, 발생된 복수의 빔을 이용하여 중첩된 빔을 생성하는 이색 거울, 상기 중첩된 빔을 시료 내부로 집속하는 대물렌즈, 시료에서 발생된 CARS 신호의 사이드 로브(side lobes)를 제거하는 공초점 핀홀(confocal pinhole), 및 사이드 로브가 제거된 CARS 신호를 검출하는 광검출기를 포함한다. https://scholar.dgist.ac.kr/handle/20.500.11750/60085 Title: Effect of JIN-A02, a Novel 4Th-Generation EGFR-TKI, on Multiple EGFR Mutations in Comparison With 3Rd-Generation EGFR-TKIs Author(s): Lim, S- M.; Kim, Beom Soo; Yu, Wookyung; Choi, Seong-Kyoon; Jo, A.; Seah, E.; Kim, C.; Han, S.; Cho, B. C.; Kim, Hee-Yeon Abstract: JIN-A02, a novel fourth-generation tyrosine kinase inhibitor (TKI) targeting the epidermal growth factor receptor (EGFR) C797S mutation, is currently undergoing phase 1/2 clinical trials in patients with EGFR-mutated non-small cell lung cancer (NSCLC) in Korea, the USA, and Thailand (NCT05394831). NSCLC patients harboring acquired EGFR C797S mutations often exhibit co-occurring mutations, such as exon 19 deletions or T790M, as a result of targeted therapies, leading to tumor tissue heterogeneity. This heterogeneity significantly limits therapeutic options for these patients. To address this challenge, there is an unmet need for the development of fourth-generation EGFR-TKIs capable of targeting multiple EGFR mutations and effectively suppressing heterogeneous tumor tissues. With a view to evaluating the activity of JIN-A02 against common EGFR mutations (including T790M), we conducted an in silico study to estimate its binding affinity compared with third-generation EGFR-TKIs along with an in vitro study to calculate its inhibitory concentration (IC90) in EGFR-mutated cell lines. 2025-09-07T15:00:00Z